GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
Last trade$104.39
Day change-$1.21 (-1.15%)
Day range$99.71 – $113.03
Volume415,144
Market cap$4.75B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.75B
Price / earnings
—
Price / book
1.94×
Price / sales
28.5×
EV / sales
28.32×
EV / EBITDA
-11.85×
Profitability
Earnings per share
-$9.03
Return on assets
-14.88%
Return on equity
-16.55%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.93×
Quick ratio
8.74×
Cash ratio
0.31×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$312M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GRAL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$37.54M
$44.69M
$40.79M
$43.6M
$36.19M
$35.54M
$31.84M
$38.25M
Cost of revenue
$22.17M
$57.25M
$55.09M
-$79.16M
$16.45M
$53.32M
$51.77M
-$79.67M
Gross profit
$15.36M
-$12.57M
-$14.31M
$122.75M
$19.74M
-$17.78M
-$19.93M
$117.92M
Selling, general and administrative
$82.44M
$88.37M
$73.44M
$66.38M
$62.91M
$66.45M
$80.05M
$72.64M
Research and development
$44.07M
$47.43M
$48.02M
$46.9M
$48.65M
$46.63M
$53.63M
$48.33M
Total operating expenses
$159.98M
$161.22M
$121.46M
$247.16M
$145.03M
$141.08M
$133.68M
$254.86M
Operating income
-$144.62M
-$173.78M
-$135.77M
-$124.41M
-$125.29M
-$158.85M
-$153.61M
-$136.94M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$137.32M
-$166.71M
-$127.52M
-$116.52M
-$118.72M
-$152.86M
-$146.41M
-$126.99M
Income taxes
-$33.75M
-$56.46M
-$34.34M
-$17.34M
-$29.74M
-$38.87M
-$40.2M
-$29.93M
Net income
-$103.57M
-$110.25M
-$93.19M
-$99.18M
-$88.98M
-$113.99M
-$106.21M
-$97.07M
Net income attributable to common shareholders
-$103.57M
-$110.25M
-$93.19M
-$99.18M
-$88.98M
-$113.99M
-$106.21M
-$97.07M
EBITDA
-$106.14M
-$109.67M
-$96.97M
-$85.5M
-$86.31M
-$91.68M
-$114.33M
-$97.5M
Basic earnings per share
-$2.21
-$2.56
-$2.29
-$2.43
-$2.46
-$3.18
-$3.10
-$2.89
Diluted earnings per share
-$2.21
-$2.56
-$2.29
-$2.43
-$2.46
-$3.18
-$3.10
-$2.89
Recent news
Company coverage with links to the original publishers.
Grail's stock surged 80% following a positive FDA panel vote on its Galleri multi-cancer early detection test. However, the article warns investors that while FDA approval and insurer adoption are important, the critical risk factor is the price insurers will be willing to pay for the $949 test, which depends on cost-benefit analyses and clinical data.
Grail, spun off from Illumina in 2024, develops the Galleri blood test for early cancer detection. The company has grown revenue from $93M (2023) to $147M (2025) through cash-only sales and is expected to reach $181M in 2026. An FDA panel recently endorsed premarket approval with three affirmative votes, potentially supporting FDA approval by 2027. Despite trading at 21x 2028 sales, analysts believe the stock could be undervalued if FDA approval comes early and adoption accelerates.
A securities class action lawsuit has been filed against PicS N.V. (NASDAQ: PICS) alleging the company made materially false and misleading statements in its January 2026 IPO by failing to disclose internal findings of deficient credit evaluation policies discovered in December 2025. The lawsuit claims these omissions masked severe portfolio deterioration, heightened default risks, and increased non-performing loans. Post-IPO disclosures revealed R$590 million in loan reclassifications and a doubled default formation rate, causing the stock to plummet over 50% from its $19.00 IPO price to under $9.00. The lead plaintiff deadline is August 4, 2026.
Hagens Berman has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging the company misled investors about its NHS-Galleri cancer screening trial's design and efficacy. GRAIL failed to meet the trial's primary endpoint on February 19, 2026, causing the stock to plummet 50.55% and erasing $2.2 billion in market capitalization. The lead plaintiff deadline is August 4, 2026.
Rosen Law Firm has filed class action lawsuits against Park Ha Biological Technology Co., Ltd. (PHH, BYAH) for securities fraud involving false statements and undisclosed fraudulent stock promotion schemes during December 2024-July 2025. A separate lawsuit targets GRAIL, Inc. (GRAL) with an August 4, 2026 deadline for investors to secure counsel. Both cases allege material misstatements and failure to disclose adverse facts affecting stock prices.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.